^
Association details:
Evidence:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Go to data
Title:

The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors

Excerpt:
Known deleterious or suspected deleterious germline or somatic BRCA1/2 mutations or with documented HRD
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trial

Published date:
07/20/2023
Excerpt:
Patients with EOC with BRCAmut and/or HRD had an ORR of 30.4% (seven of 23 patients), with a CR rate of 8.7%...In conclusion, pamiparib in combination with tislelizumab showed evidence of antitumour activity in patients with advanced solid tumours, particularly those with BRCAmut and/or HRD tumours, with a manageable safety profile in keeping with the class of agents. This study supports further investigation of this combination strategy, particularly in patients with TNBC with BRCAmut and/or HRD.
DOI:
10.1038/s41416-023-02349-0